Bulletin de la Société de pathologie exotique

, Volume 107, Issue 4, pp 234–237

Prévalence des complications métaboliques à 10 ans de traitements antirétroviraux au Sénégal

  • A. Diouf
  • A. Cournil
  • groupe d’étude de la Cohorte ANRS 1215
Santé Publique / Public Health

Résumé

Les prévalences de lipodystrophie, d’hypertension et de diabète chez les patients de la cohorte encore suivis après une médiane de 9 ans de traitement étaient de 37 %, 28 % et 14 %, respectivement. Cette étude confirme l’association entre stavudine et lipodystrophie plus particulièrement la lipoatrophie ; et révèle une relation entre durée de traitement et diabète. Ces résultats soulignent l’importance d’un dépistage systématique de ces anomalies dans le suivi du patient VIH.

Mots clés

Cohorte ANRS 1215 PVVIH VIH ARV Lipodystrophie Hypertension artérielle Diabète Hypercholestérolémie Hypertriglycéridémie Stavudine Dakar Sénégal Afrique intertropicale 

Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal

Abstract

Among the patients of the cohort still followed after a median of 9 years of antiretroviral treatment (ART), 37% had lipodystrophy, 28% had hypertension and 14% presented with diabetes. This study confirms the association between stavudine and lipodystrophy particulary lipoatrophy and shows that a longer duration of ART was associated with the presence of diabetes. These results highlight the need to implement programs for prevention of cardiovascular risk factors in HIV patients from resource-constrained settings.

Keywords

ANRS 1215 Cohort PLHIV HIV ART Lipodystrophy Hypertension Diabetes Hypercholesterolemia Hypertriglyceridemia Stavudine Dakar Senegal Sub-Saharan Africa 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Brown TT, Cole SR, Li X, et al (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Medi 165(10) 1179–84CrossRefGoogle Scholar
  2. 2.
    Capeau J, Bouteloup V, Katlama C, et al (2012) Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 26(3):303–314PubMedCrossRefGoogle Scholar
  3. 3.
    Diouf A, Cournil A, Ba-Fall K, et al (2012) Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment since 1998 in Senegal: Prevalence and Associated Factors. ISRN AIDS 2012:621565PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Galli M, Veglia F, Angarano G, et al (2003) Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 34(1):58–61PubMedCrossRefGoogle Scholar
  5. 5.
    Mercier S, Gueye NF, Cournil A, et al (2009) Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4-to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr 51(2):224–230PubMedCrossRefGoogle Scholar
  6. 6.
    Mutimura E, Stewart A, Rheeder P, Crowther NJ (2007) Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 46(4):451–455PubMedCrossRefGoogle Scholar
  7. 7.
    Taverne B, Desclaux A, Sow PS, et al (2012) Evaluation de l’impact bio-clinique et social, individuel et collectif, du traitement ARV chez des patients VIH-1 pris en charge depuis 10 ans dans le cadre de l’ISAARV — Cohorte ANRS 1215. Rapport final. IRD/CRCF [http://hal.ird.fr/ird-00718213]Google Scholar
  8. 8.
    van Griensven J, De Naeyer L, Mushi T, et al (2007) High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 101(8):793–798PubMedCrossRefGoogle Scholar
  9. 9.
    Yao J, Yu W, Li T, Luo L, et al (2011) The pilot study of DXA assessment in Chinese HIV-infected men with clinical lipodystrophy. J Clin Densitom 14(1):58–62PubMedCrossRefGoogle Scholar
  10. 10.
    Zannou DM, Denoeud L, Lacombe K, et al (2009) Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther 14:371–380PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2014

Authors and Affiliations

  • A. Diouf
    • 1
  • A. Cournil
    • 2
  • groupe d’étude de la Cohorte ANRS 1215
  1. 1.Centre régional de recherche et de formation à la prise en charge clinique de Fann (CRCF)CHU de FannDakarSénégal
  2. 2.UMI 233 TransVIHMICentre IRD de MontpellierMontpellier cedex 5France

Personalised recommendations